



Toxicological Profile for Carbon Disulfide

Draft for Public Comment

October 2024



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

CS274127-A

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

This information is distributed solely for the purpose of pre dissemination public comment under applicable information quality guidelines. It has not been formally disseminated by the Agency for Toxic Substances and Disease Registry. It does not represent and should not be construed to represent any agency determination or policy.

FOREWORD

This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, intermediate, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine the levels of exposure that present a significant risk to human health due to acute-, intermediate-, and chronic-duration exposures; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public. ATSDR plans to revise these documents in response to public comments and as additional data become available. Therefore, we encourage comments that will make the toxicological profile series of the greatest use.

Electronic comments may be submitted via: www.regulations.gov. Follow the on-line instructions for submitting comments.

Written comments may also be sent to: Agency for Toxic Substances and Disease Registry
Office of Innovation and Analytics
Toxicology Section
1600 Clifton Road, N.E.
Mail Stop S106-5
Atlanta, Georgia 30329-4027

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA Section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health-related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under Section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher M. Reh, Ph.D.
Associate Director,
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

VERSION HISTORY

Date	Description
October 2024	Draft for public comment toxicological profile released
August 1996	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Custodio Muianga, M.P.H., Ph.D., C.H.M.M. (Lead)	Kimberly Zaccaria, Ph.D., D.A.B.T.
Breanna Alman, M.P.H.	Jennifer L. Rhoades, B.A.
Brittany Szafran, D.V.M., Ph.D.	Connor McGuire, Ph.D.
	Deborah M. Herber, Ph.D.
	Julie M. Klotzbach, Ph.D.
	Jenny S. Crisman, B.S.
	Mario Citra, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Sciences; NCEH, Division of Environmental Health Science and Practice; EPA, Office of Research and Development; EPA, Office of Water.

PEER REVIEWERS

1. Paul Blanc, M.D., Professor, School of Medicine, University of California San Francisco, San Francisco, California
2. Fuyong Song, Ph.D., Department of Health Toxicology and Nutrition, School of Public Health, Cheeloo College of Medicine, Shandong University, Shandong, China
3. James Bus, Ph.D., Senior Managing Scientist, Exponent, Alexandria, Virginia

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS.....	vii
LIST OF FIGURES	ix
LIST OF TABLES.....	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS.....	2
1.3 MINIMAL RISK LEVELS (MRLs)	7
CHAPTER 2. HEALTH EFFECTS.....	11
2.1 INTRODUCTION.....	11
2.2 DEATH	52
2.3 BODY WEIGHT	57
2.4 RESPIRATORY.....	59
2.5 CARDIOVASCULAR.....	60
2.6 GASTROINTESTINAL.....	73
2.7 HEMATOLOGICAL	74
2.8 MUSCULOSKELETAL	77
2.9 HEPATIC	78
2.10 RENAL	91
2.11 DERMAL	94
2.12 OCULAR	94
2.13 ENDOCRINE.....	98
2.14 IMMUNOLOGICAL	103
2.15 NEUROLOGICAL.....	103
2.16 REPRODUCTIVE	127
2.17 DEVELOPMENTAL	135
2.18 OTHER NONCANCER.....	138
2.19 CANCER.....	142
2.20 GENOTOXICITY	143
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS.....	147
3.1 TOXICOKINETICS.....	147
3.1.1 Absorption.....	147
3.1.2 Distribution	150
3.1.3 Metabolism.....	152
3.1.4 Excretion	155
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	157
3.1.6 Animal-to-Human Extrapolations	158
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.....	158
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	161

3.3.1	Biomarkers of Exposure.....	161
3.3.2	Biomarkers of Effect	162
3.4	INTERACTIONS WITH OTHER CHEMICALS	164
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		166
4.1	CHEMICAL IDENTITY	166
4.2	PHYSICAL AND CHEMICAL PROPERTIES	166
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE.....		169
5.1	OVERVIEW	169
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	170
5.2.1	Production	170
5.2.2	Import/Export.....	172
5.2.3	Use	173
5.2.4	Disposal.....	174
5.3	RELEASES TO THE ENVIRONMENT.....	175
5.3.1	Air	175
5.3.2	Water.....	179
5.3.3	Soil	180
5.4	ENVIRONMENTAL FATE	181
5.4.1	Transport and Partitioning.....	181
5.4.2	Transformation and Degradation	182
5.5	LEVELS IN THE ENVIRONMENT	183
5.5.1	Air	185
5.5.2	Water.....	186
5.5.3	Sediment and Soil	188
5.5.4	Other Media	188
5.6	GENERAL POPULATION EXPOSURE.....	188
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	189
CHAPTER 6. ADEQUACY OF THE DATABASE		194
6.1	EXISTING INFORMATION ON HEALTH EFFECTS	194
6.2	IDENTIFICATION OF DATA NEEDS.....	196
6.3	ONGOING STUDIES.....	203
CHAPTER 7. REGULATIONS AND GUIDELINES		204
CHAPTER 8. REFERENCES		206
 APPENDICES		
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS		A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR CARBON DISULFIDE		B-1
APPENDIX C. FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR CARBON DISULFIDE		C-1
APPENDIX D. USER'S GUIDE.....		D-1
APPENDIX E. QUICK REFERENCE FOR HEALTH CARE PROVIDERS		E-1
APPENDIX F. GLOSSARY		F-1
APPENDIX G. ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....		G-1

LIST OF FIGURES

1-1. Health Effects Found in Humans and Animals Following Inhalation Exposure to Carbon Disulfide	3
1-2. Health Effects Found in Animals Following Oral Exposure to Carbon Disulfide	4
1-3. Summary of Sensitive Targets of Carbon Disulfide – Inhalation.....	8
1-4. Summary of Sensitive Targets of Carbon Disulfide – Oral.....	9
2-1. Overview of the Number of Studies Examining Carbon Disulfide Health Effects	16
2-2. Levels of Significant Exposure to Carbon Disulfide – Inhalation.....	35
2-3. Levels of Significant Exposure to Carbon Disulfide – Oral	48
3-1. Proposed Metabolic Pathways for Carbon Disulfide.....	153
5-1. Number of NPL Sites with Carbon Disulfide Contamination	169
6-1. Summary of Existing Health Effects Studies on Carbon Disulfide by Route and Endpoint	195

LIST OF TABLES

1-1. Provisional Minimal Risk Levels (MRLs) for Carbon Disulfide	10
2-1. Levels of Significant Exposure to Carbon Disulfide – Inhalation.....	17
2-2. Levels of Significant Exposure to Carbon Disulfide – Oral	44
2-3. Levels of Significant Exposure to Carbon Disulfide – Dermal	51
2-4. Results of Epidemiological Studies Evaluating Mortality in Viscose Rayon Workers.....	53
2-5. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Cardiovascular Effects.....	61
2-6. Cohort Studies Evaluating Associations Between Occupational Exposure to Carbon Disulfide and Heart Disease Included in the Meta-Analysis Conducted by Tan et al. (2002).....	69
2-7. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Gastrointestinal Effects.....	73
2-8. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Hematological Effects	75
2-9. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Blood Lipid Levels.....	79
2-10. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Other Hepatic Endpoints	89
2-11. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Renal Effects.....	92
2-12. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Ophthalmology	95
2-13. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Endocrine Effects	98
2-14. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Peripheral Neuropathy.....	106
2-15. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Neuropsychological or Cognitive Effects.....	112
2-16. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Other Neurological Effects.....	117
2-17. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Male Reproductive Effects	128
2-18. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Female Reproductive Effects	134

2-19. Results of Epidemiological Studies Evaluating Exposure to Carbon Disulfide and Metrics of Diabetes and/or Metabolic Syndrome	138
2-20. Genotoxicity of Carbon Disulfide <i>In Vitro</i>	143
2-21. Genotoxicity of Carbon Disulfide <i>In Vivo</i>	144
4-1. Chemical Identity of Carbon Disulfide.....	166
4-2. Physical and Chemical Properties of Carbon Disulfide.....	166
5-1. Facilities that Produce, Process, or Use Carbon Disulfide	171
5-2. Releases to the Environment from Facilities that Produce, Process, or Use Carbon Disulfide.....	175
5-3. Carbon Disulfide Emissions to the Air Based on 2017 National Emissions Inventory.....	177
5-4. Global Annual Emissions of Carbon Disulfide from Oceans.....	180
5-5. Lowest Limit of Detection Based on Standards	183
5-6. Summary of Environmental Levels of Carbon Disulfide	184
5-7. Carbon Disulfide Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	184
5-8. Summary of Annual Concentration of Carbon Disulfide ($\mu\text{g}/\text{m}^3$) Measured in Ambient Air at Locations Across the United States	185
5-9. Personal Air Exposure Measurements by Job Type Before and After Technical Improvements	186
5-10. Summary of Concentrations of Carbon Disulfide ($\mu\text{g}/\text{L}$) Measured in Surface and Groundwater Across the United States.....	187
5-11. Reasonable Maximum Exposure of Carbon Disulfide for Daily Inhalation Dose and Administered Dermal Dose in $\mu\text{g}/\text{kg}/\text{day}$ for the Target Person	189
5-12. Carbon Disulfide Personal Air Monitoring (ppm) in a Rayon Factory in 1992 and 2009	191
5-13. 2-Thiothiazolidine-4-carboxylic Acid (mg/g Creatinine) Concentration in Urine of Workers in a Rayon Factory in 1992 and 2009.....	192
5-14. Weekday Urinary Levels of 2-Thiothiazolidine-4-carboxylic Acid in Rubber Workers by Department	192
7-1. Regulations and Guidelines Applicable to Carbon Disulfide	204